Atea Pharmaceuticals, Inc. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • October 26th, 2020 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] shares of Common Stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ATEA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 26th, 2020 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of ______________, 20[20] between Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).
AMENDED AND RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • November 7th, 2024 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Employment AgreementEmployment Agreement • March 30th, 2021 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (this “Agreement”), dated as of November 3, 2020 (the “Effective Date”), is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and John Vavricka (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”).
125 SUMMER STREET BOSTON, MASSACHUSETTS OFFICE LEASE AGREEMENT BETWEEN OPG 125 SUMMER OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND ATEA PHARMACEUTICALS, INC., a Delaware corporation, AS TENANTOffice Lease Agreement • October 9th, 2020 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations
completeness of the Construction Documents submitted to Landlord. The Construction Documents shall comply with the Building’s construction rules and regulations, including without limitation those designed to maintain a uniform exterior appearance of the Building. Tenant shall be solely responsible for the timely preparation and submission to Landlord of the Construction Documents by the Tenant Plan Submission Date. Landlord shall use reasonable efforts to review and approve (or provide comments on) the Construction Documents, in a written response, within ten (10) Business Days after the same are delivered to Landlord, provided that Landlord reserves the right to extend such review period if reasonably required to review, or to cause Landlord’s third-party engineer(s) to review, any structural elements or other special elements of the Initial Tenant Work. Tenant shall promptly cause the Construction Documents to be corrected or revised to address Landlord’s comments and resubmitted to
CONSULTING AGREEMENTConsulting Agreement • August 8th, 2022 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This CONSULTING AGREEMENT (this “Agreement”), is made this 10th day of June, 2022 by Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Bruce Polsky, M.D. (the “Consultant”).
ATEA PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • October 23rd, 2020 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of May 19, 2020, by and among Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Founder (as defined below), each of the investors listed on Schedule A hereto (together with any subsequent investors or transferees, who become parties hereto as “Investors” pursuant to Subsections 11.9(a) or 11.12 below, the “Investors”), and those certain stockholders of the Company listed on Schedule B (together with any subsequent stockholders or transferees, who become parties hereto as “Key Holders” pursuant to Subsection 11.9(b) or 11.12 below, the “Key Holders,” and together collectively with the Investors, the “Stockholders”).
Amendment #1 to Consulting AgreementConsulting Agreement • October 9th, 2020 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This Amendment No. 1 to the Consulting Agreement (“Amendment”) is made as of August 8, 2019 (“Effective Date”), by and between Atea Pharmaceuticals, Inc. (“Company”) and Danforth Advisors, LLC (“Consultant” or “Danforth”) and amends that certain Consulting Agreement by and between the Company and Danforth made effective as of July 31, 2019 (“ Agreement” ). Capitalized terms used but not defined herein shall have the respective meaning set forth in the Agreement.
LICENSE AGREEMENT by and between MSD INTERNATIONAL GMBH and ATEA PHARMACEUTICALS, INC.License Agreement • February 28th, 2022 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”), dated as of December 23, 2021 (the “Effective Date”), is made by and between MSD International GmbH, a company organized and existing under the laws of Switzerland (“MSD”), and Atea Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“Licensee”). MSD and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
ContractSublease Amendment • August 8th, 2022 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations
SUBLEASESublease • July 23rd, 2021 • Atea Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
THIS AGREEMENT OF SUBLEASE (“Sublease”) made as of July 19, 2021, by and between DataRobot, Inc., a Delaware corporation, having an office at 225 Franklin Street, Boston, MA 02110 (“Sublandlord”), and Atea Pharmaceuticals, Inc., a Delaware corporation, having an office at 125 Summer Street, Boston, MA 02110 (“Subtenant”).
